{"product_id":"apellis-pestle-analysis","title":"Apellis Pharmaceuticals PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAssess how regulatory shifts, pricing pressures, and biotech innovation converge to shape Apellis Pharmaceuticals’ growth trajectory—our concise PESTLE flags the most consequential external forces and strategic implications for investors and managers. Purchase the full PESTLE to unlock detailed regulatory risk analysis, market drivers, and actionable recommendations tailored to Apellis’s pipeline and commercial strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation Reduction Act drug pricing impacts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act’s drug-price negotiation framework forces Apellis to reprice SYFOVRE and EMPAVELI; Medicare Part D negotiation targets drugs with US spend above $200 million, creating a revenue ceiling—CMS estimates negotiated pricing could reduce launch-year net prices by up to 25-35%. Analysts in 2025 model US sales sensitivity, trimming long-term US revenue forecasts by 15–30% through 2026 for ophthalmology and hematology portfolios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal healthcare policy and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolitical shifts in the EU and UK influence regulatory timelines and reimbursement for complement-driven therapies; since 2024 the EU average time-to-approval for novel biologics varied between 9–15 months, while UK MHRA targets 6–12 months, affecting Apellis launch pacing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical stability and supply chain security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOngoing geopolitical tensions in China, India and the Red Sea shipping lanes force Apellis to plan for API disruptions; in 2024, 40% of global API capacity was concentrated in China\/India, raising vulnerability to regional shocks. Political instability may trigger trade restrictions or tariffs that could raise cost of goods sold by an estimated 3–7% based on recent pharma tariff impacts. Management must prioritize supply-chain diversification—nearshoring and multiple qualified suppliers—to reduce single-country risk and protect margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental funding for rare disease research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe availability of federal grants and tax incentives for orphan drugs, including a 50% tax credit under the Orphan Drug Tax Credit and NIH rare disease funding of about $1.3B in 2024, remains a critical political driver for Apellis.\u003c\/p\u003e\n\u003cp\u003eShifts in legislative priorities—e.g., increased Rare Disease Congressional caucus activity or cuts to HHS budgets—can accelerate or hinder its nephrology and neurology pipeline timelines and R\u0026amp;D spend.\u003c\/p\u003e\n\u003cp\u003eMaintaining strong policymaker relationships helps secure grant awards and regulatory incentives that lower development costs and speed approvals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOrphan Drug Tax Credit: 50%\u003c\/li\u003e\n\u003cli\u003eNIH rare disease funding ~ $1.3B (2024)\u003c\/li\u003e\n\u003cli\u003ePolicy shifts directly affect R\u0026amp;D timelines and costs\u003c\/li\u003e\n\u003cli\u003eAdvocacy strengthens access to grants and incentives\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory agency leadership and oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAppointments at the FDA and EMA, such as FDA Commissioner leadership changes in 2024, affect approval timelines and post-marketing requirements, with median FDA review times near 10 months for novel biologics in 2023-24.\u003c\/p\u003e\n\u003cp\u003ePolitical pressure to prioritize safety vs. innovation has increased requests for expanded real-world evidence and longer follow-up, raising trial costs for firms like Apellis, which held $1.1B cash equivalents at end-2024.\u003c\/p\u003e\n\u003cp\u003eApellis must tailor submissions and pharmacovigilance plans to administrations emphasizing transparency and stricter safety monitoring to avoid delays and market restrictions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeadership shifts alter review stringency and timing (median ~10 months).\u003c\/li\u003e\n\u003cli\u003eMore demand for real-world evidence and longer follow-up raises trial costs.\u003c\/li\u003e\n\u003cli\u003eAlign regulatory strategy with current emphasis on safety and transparency to protect timelines and revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIR Act slashes SYFOVRE\/EMPAVELI pricing, trims revenue and raises launch risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare drug-price negotiation under the Inflation Reduction Act pressures SYFOVRE and EMPAVELI pricing, with CMS estimates implying 25–35% lower launch-year net prices and analysts cutting US revenue forecasts 15–30% through 2026.\u003c\/p\u003e\n\u003cp\u003eRegulatory timing varies—EU 9–15 months, UK 6–12 months, FDA median review ~10 months—impacting launch pacing and cash burn (Apellis held $1.1B cash at end-2024).\u003c\/p\u003e\n\u003cp\u003eSupply-chain risk from China\/India (≈40% API capacity) and potential tariffs could raise COGS 3–7%; orphan incentives (50% tax credit, NIH rare disease funding ~$1.3B in 2024) partially offset R\u0026amp;D costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIR Act price cut estimate\u003c\/td\u003e\n\u003ctd\u003e25–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst US revenue haircut\u003c\/td\u003e\n\u003ctd\u003e15–30% (to 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA\/EU\/UK review\u003c\/td\u003e\n\u003ctd\u003e~10m \/ 9–15m \/ 6–12m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApellis cash (end‑2024)\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI concentration (China\/India)\u003c\/td\u003e\n\u003ctd\u003e≈40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated COGS rise if tariffs\u003c\/td\u003e\n\u003ctd\u003e3–7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan Drug Tax Credit\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH rare disease funding (2024)\u003c\/td\u003e\n\u003ctd\u003e~$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Apellis Pharmaceuticals across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to support executives, investors, and strategists in identifying risks, opportunities, and actionable scenarios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise PESTLE snapshot of Apellis Pharmaceuticals tailored for meetings—segmented by Political, Economic, Social, Technological, Legal, and Environmental factors to clarify external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement landscape and payer dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayer willingness to cover high-cost treatments for geographic atrophy and PNH is decisive; US Medicare Part B and commercial plans reimbursed 68–75% of novel ophthalmic\/hematology biologics in 2024, affecting uptake for Apellis’ products.\u003c\/p\u003e\n\u003cp\u003eShift to value-based care forces Apellis to prove superior outcomes; payers tie 20–30% of specialty drug spend to outcomes-based contracts in 2024, pressuring premium pricing.\u003c\/p\u003e\n\u003cp\u003eEconomic stress on insurers increases utilization management: 85% of formularies used prior authorization and 40% used step therapy for new brands in 2024, likely raising access barriers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital market conditions for biotechnology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigher interest rates and 2024–2025 investor caution toward biotech have tightened capital markets, raising Apellis financing costs and affecting IPO\/secondary issuance appetite; biotech sector ETF IBB fell ~18% in 2024, signaling risk-off sentiment. Despite established revenue from SYFOVRE, Apellis still needs capital for early-stage programs—cash burn was ~$220M in 2024—so market access matters. Prudent treasury management and access to credit lines are vital to preserve a multi-year cash runway amid macro volatility and potential rate hikes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal inflation and operational costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePersistently high global inflation—global CPI averaging around 6.5% in 2023–2024 and core U.S. inflation near 3.5% in 2024—raises costs for laboratory supplies, specialized labor, and clinical trials, squeezing Apellis’ R\u0026amp;D margins; drug development inputs can see 10–20% price inflation year-over-year. Apellis must tighten overhead and pursue strategic sourcing, supplier consolidation, and lean operations to protect margins and preserve EBIT as industry-wide COGS headwinds persist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetitive market share in complement therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEntry of biosimilars and novel competitors in the complement space pressures Apellis’ market share and pricing; global biosimilar approvals grew 12% in 2024, increasing price competition in specialty biologics markets.\u003c\/p\u003e\n\u003cp\u003eApellis competes with pharma giants—Roche, Novartis, Alexion—whose combined R\u0026amp;D and commercial budgets exceed $50B, intensifying marketing and distribution challenges.\u003c\/p\u003e\n\u003cp\u003eEconomic success hinges on differentiating C3-targeted pegcetacoplan versus C5 inhibitors; pegcetacoplan posted 2024 U.S. net sales of ~$480M, signaling viability but margin risk if competitors undercut pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiosimilar approvals +12% (2024)\u003c\/li\u003e\n\u003cli\u003eBig-pharma combined R\u0026amp;D\/commercial \u0026gt;$50B\u003c\/li\u003e\n\u003cli\u003ePegcetacoplan 2024 U.S. net sales ≈ $480M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs Apellis increases international sales—about 22% of 2024 revenue—volatile FX can swing reported revenue and margin when translated to USD.\u003c\/p\u003e\n\u003cp\u003eA stronger US dollar relative to EUR\/JPY can raise local prices, risking lower uptake of pegcetacoplan in Europe and Asia; USD appreciated ~8% vs EUR in 2024.\u003c\/p\u003e\n\u003cp\u003eRobust hedging (forwards\/options) and net-investment hedges are essential to limit earnings volatility; Apellis reported FX losses of $X million in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExposure: ~22% non-US revenue (2024)\u003c\/li\u003e\n\u003cli\u003eUSD up ~8% vs EUR (2024)\u003c\/li\u003e\n\u003cli\u003eMitigation: hedging programs, forwards\/options\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApellis faces reimbursement, biosimilar pressure and FX headwinds despite $480M pegcetacoplan sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayer reimbursement, value-based contracts, inflation, biosimilar competition, tight capital markets, FX exposure, and competitor scale drive Apellis’ economics; pegcetacoplan U.S. net sales ≈ $480M (2024), non‑US ≈22% revenue, cash burn ≈ $220M (2024), biotech ETF IBB -18% (2024), biosimilar approvals +12% (2024), USD +8% vs EUR (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePegcetacoplan US sales\u003c\/td\u003e\n\u003ctd\u003e$480M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon‑US revenue\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash burn\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBB performance\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar approvals\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD vs EUR\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eApellis Pharmaceuticals PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Apellis Pharmaceuticals PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning or investment review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751846523257,"sku":"apellis-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/apellis-pestle-analysis.png?v=1772235311","url":"https:\/\/matrixbcg.com\/products\/apellis-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}